Fig. 6

Forest plots of the subgroup analysis in patients with advanced. NSCLC according to the PD-L1 expression. CT: chemotherapy; Nivo-CT: nivolumab plus chemotherapy,; Durv-CT: duvalumab plus chemotherapy; Tis-CT: Tislelizumab plus chemotherapy